Direct Selective Laser Trabeculoplasty (DSLT) for Reducing Eye Pressure in Non-Caucasian Patients With Open Angle Glaucoma
Sponsored by Select Eye Care
About this trial
Last updated 9 months ago
Study ID
Status
Type
Phase
Placebo
Accepting
Trial Timing
Started a year ago
What is this trial about?
What are the participation requirements?
Inclusion Criteria
* Adult patients of Black African descent scheduled to undergo DSLT treatment in one or both eyes.
* Diagnosis of mild to moderate primary open angle glaucoma (POAG).
* Mild to moderate POAG will be defined as Stage 2 or better of the Hodapp-Anderson-Parrish glaucoma staging system.
* Treatment naive or washed out IOP at time 0 ranging from ≥ 21 through 32 mm Hg.
Exclusion Criteria
* Screened patients who were on IOP-lowering medications who did not successfully complete medication washout at the time of the procedure (time 0).
* Previous glaucoma surgeries/interventions:
* Patients who have undergone prior glaucoma-related procedures (e.g., trabeculectomy, laser trabeculoplasty, MIGS, or tube shunt).
* Secondary glaucoma:
* Patients with secondary forms of glaucoma, such as angle-closure glaucoma, neovascular glaucoma, or glaucoma resulting from trauma or other systemic diseases.
* Other significant ocular conditions including advanced cataracts, retinal diseases (e.g., age-related macular degeneration), or any condition that might complicate the assessment of intraocular pressure (IOP) or visual function as deemed by the investigator.
* Subjects who are pregnant, breast-feeding, or intend to become pregnant during the study period as determined by verbal inquiry.
